GILD · Gilead Sciences, Inc
Price
Snapshot
50 fields · last close| Market Cap | $193.7B |
| P/E | 22.76 |
| Float | 1.24B |
| Beta | 0.40 |
| Volatility | 10.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 80.9 |
| Price | 154.59 |
| Change | −1.02% |
| Prev Close | 156.19 |
| Open | 157.32 |
| Day Low | 155.62 |
| Day High | 157.57 |
| Avg Vol | 6 |
| Avg $ Vol | $912.5M |
| 52W High | 160.51 |
| 52W Low | 114.02 |
| 52W Pos | 87.3% |
| From High | −3.69% |
| From Low | +35.58% |
| Max DD 1Y | −22.03% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +3.08% |
| SMA 50 | +5.28% |
| SMA 200 | +12.00% |
| RSI (14) | 63.4 |
| Vol 30D | 23.9% |
| Vol 90D | 28.0% |
| 1Y Range | 114–161 |
| Daily bars | 536 |
| Perf Week | +3.32% |
| Perf Month | +3.51% |
| Perf Quarter | +17.25% |
| Perf Half Y | +13.48% |
| Perf Year | +32.03% |
| Perf YTD | +27.13% |
| Prev Day | −1.02% |
| Clavix | A- |
| Debt / Eq | 1.10 |
| Curr Ratio | 1.55 |
| Int Cover | 120.3× |
| FCF Margin | 32.1% |
| Rev Growth | +2.4% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 1 / 35 |
What GILD does
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19.
Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program.
The company was incorporated in 1987 and is headquartered in Foster City, California.
Clavix risk grade
regraded every trading dayGILD grades A-, 80.9 of 100. Steadiest on Macro Resilience (70), most exposed on Sector Resilience (61, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 1 of 35 in Biotechnology by Clavix score.
How rough the ride is
| GILD | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.40 | 0.51 |
| Volatilityannualized | 10.0% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −22.0% | — |
| Typical daily movemedian absolute daily change | 1.06% | — |
| Days beyond ±3%of the last 252 sessions | 18 (7%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| GILD | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.40 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| GILD | |
|---|---|
| 1 week | +3.3% |
| 1 month | +3.5% |
| Year to date | +27.1% |
| 1 year | +32.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| GILD | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 11 Sep |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 26 · 3 |
| Directionarticles whose tone is improving vs worsening | 26 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| GILD | |
|---|---|
| Revenue growthyear over year | +2.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGilead Sciences is expanding its oncology pipeline through a deal with Vir Biotechnology worth up to $1.74 billion in additional milestone payments, targeting three novel cancer therapies.
Gilead Sciences is expanding its cancer drug development through a deal with Vir Biotechnology that could pay Vir up to $1.74 billion in milestone payments if certain goals are met, covering three experimental cancer treatments.
Vir Biotechnology and Gilead Sciences announced a collaboration to jointly develop three new cancer treatments called T-cell engagers, which are drugs designed to link the immune system's T-cells directly to solid tumor cells so the immune cells can destroy them.
Royal Bank of Canada raised its price target on Gilead Sciences shares from $123 to $126 but kept a 'sector perform' rating, which is analyst language for expecting the stock to perform about in line with its sector.
Royal Bank of Canada raised its price target on Gilead Sciences stock from $123 to $126 and kept a 'sector perform' rating, which means it expects the shares to perform roughly in line with other drug companies. The note was issued Thursday.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc | A- | $233.8B | 26.74 | 0.44 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $126.7B | 28.75 | 0.29 | Compare |
| MRNA | Moderna Inc | F | $87.04B | — | 1.17 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.41B | 18.81 | 0.13 | Compare |
| ABBV | AbbVie Inc | B+ | $504.4B | 79.93 | 0.19 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.